跳转至内容
Merck
CN

YTHDC2 Promotes Malignant Phenotypes of Breast Cancer Cells.

Journal of oncology (2022-10-18)
Atsushi Tanabe, Takatoshi Nakayama, Jo Kashiyanagi, Hitoshi Yamaga, Yoshihiko Hirohashi, Toshihiko Torigoe, Fukino Satomi, Hiroaki Shima, Hideki Maeda, Goro Kutomi, Ichiro Takemasa, Hiroeki Sahara
摘要

YTH domain-containing 2 (YTHDC2) is known to be an important regulator for RNA metabolism. Here, we show that YTHDC2 is essential for breast cancer tumorigenesis and metastasis. We examined YTHDC2 expression levels by immunohistochemistry in human breast tumor tissues from 99 patients and found a significantly positive correlation between the YTHDC2 expression level and the tumor stage. We established YTHDC2-knocked-down cell lines using four breast cancer cell lines with different subtypes. Knockdown of YTHDC2 attenuated the sphere-forming and the metastatic ability of breast cancer cells. Although stemness and EMT markers, such as SOX2, c-MYC, and NANOG, were downregulated in several YTHDC2-knocked-down breast cancer cells, a common target gene of YTHDC2 in breast cancer cells was not identified. These findings suggest that while YTHDC2 is involved in malignant progression of breast cancers, the mechanism by which YTHDC2 regulates those phenotypes is different between subtypes of breast cancers.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid